China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
 Maximize Value of Formulary Data for Life Sciences Commercial Teams - EconoTimes)
BURLINGTON, Mass. and SAN FRANCISCO, June 12, 2017 -- Zephyr Health, the leading Insights-as-a-Service solution provider for Life Sciences companies, and Decision Resources Group (DRG), one of the healthcare industry’s most trusted providers of market intelligence and global data products and services, today announced the release of Provider Market Access. The first advanced analytics product of its kind, Provider Market Access operationalizes formulary status for commercial (sales and marketing) teams in Life Sciences companies for improved account planning, physician engagement and sales effectiveness.
“These groundbreaking capabilities help maximize sales opportunities and accelerate brand performance by contextualizing market access status into actionable insights,” said Lance Scott, President and CEO, Zephyr Health. “Getting real-time visibility into the formulary and reimbursement status of a company’s product at the individual physician level will transform how market access data is managed within commercial teams and broaden today’s current, centralized view.”
This new suite of advanced analytics, available within the Zephyr Illuminate™ platform, combines DRG’s gold-standard Fingertip Formulary market access data with hundreds of public, internal and external data sources linked in Zephyr Illuminate to deliver comprehensive provider-centric market access insights. The enhanced solution includes “Market Access Potential,” which identifies sales opportunities based upon formulary coverage compared to competing therapies, and “Market Access Recommendations”, which generate real-time notifications to field representatives with actionable next steps based upon changes to formulary status.
Baird Stiles, DRG’s Senior Vice President of Market Access Product Solutions remarked “As the healthcare landscape continues to shift, connecting flexible market access strategies to field sales teams is one of the primary keys to success. Organizations that can quickly and effectively respond to advantageous formulary and policy shifts are better positioned to maximize their brand access. DRG and Zephyr Health are excited to provide Life Sciences organizations with an actionable tool that enables sales and account teams to engage in immediate real-time, data driven conversations as well as develop targeted, impactful, long-term market access strategies.”
Provider Market Access is the first co-innovation area for Zephyr Health and DRG. The companies will continue to partner on additional opportunities to bring innovative data and insight solutions to Life Sciences companies while operating independently with their own robust product offerings.
About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG’s in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.
Visit www.DecisionResourcesGroup.com to learn more.
About Zephyr Health
Zephyr Health helps Life Sciences companies – pharmaceutical, biotech, medical device and diagnostics – engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate™ is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, Life Sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles. Zephyr Health's customers include several of the Top 10 Pharmaceutical, Biotech and Medical Device companies.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Media contact for DRG: Kim Gordon +1 (781) 281-6019 [email protected] Media contact for Zephyr Health: [email protected]
